Abstract
Purpose
The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based drug products. We describe a novel, nonlinear compartmental model using PET-derived data to determine the “best-fit” parameters and model-derived quantities for optimizing biodistribution of intravenously injected 124I-labeled antitumor antibodies.
Methods
As an example of this paradigm, quantitative image and kinetic analyses of anti-A33 humanized mAb (also known as “A33”) were performed in 11 colorectal cancer patients. Serial whole-body PET scans of 124I-labeled A33 and blood samples were acquired and the resulting tissue time–activity data for each patient were fit to a nonlinear compartmental model using the SAAM II computer code.
Results
Excellent agreement was observed between fitted and measured parameters of tumor uptake, “off-target” uptake in bowel mucosa, blood clearance, tumor antigen levels, and percent antigen occupancy.
Conclusion
This approach should be generally applicable to antibody–antigen systems in human tumors for which the masses of antigen-expressing tumor and of normal tissues can be estimated and for which antibody kinetics can be measured with PET. Ultimately, based on each patient’s resulting “best-fit” nonlinear model, a patient-specific optimum mAb dose (in micromoles, for example) may be derived.
Similar content being viewed by others
Notes
The association rate constant (k a) is the fractional rate of binding of the antibody to the antigen per unit concentration of unbound antigen, expressed, for example, in the unit of /M/h.
The model parameter k(i,j) (sometimes known as an “exchange rate”) is the fractional rate of transport of the A33 antibody from compartment j to compartment i, expressed, for example, in the unit of /h.
References
O’Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, et al. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med. 2011;52:1878–85.
Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, et al. (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173–80.
Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol. 2000;46:S27–32.
Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1997;94:469–74.
Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, et al. A33 antigen displays persistent surface expression. Cancer Immunol Immunother. 2008;57:1017–27.
Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787–97.
Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, et al. Quantitative-analysis of antibody localization in human metastatic colon cancer – a phase-I study of monoclonal antibody-A33. J Clin Oncol. 1990;8:1894–906.
Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, et al. Phase I/II study of iodine 131-labeled monoclonal-antibody A33 in patients with advanced colon-cancer. J Clin Oncol. 1994;12:1561–71.
Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2003;9:1347–53.
Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338–46.
Chong G, Lee F, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, et al. Phase I trial of I-131-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818–26.
Sakamoto J, Oriuchi N, Mochiki E, Asao T, Scott AM, Hoffman EW, et al. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Sci. 2006;97:1248–54.
King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, et al. Preparation and preclinical evaluation of humanized A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72:1364–72.
Barendswaard EC, Scott AM, Divgi CR, Williams C Jr, Coplan K, Riedel E, et al. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int J Oncol. 1998;12:45–53.
Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, et al. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 2001;42:764–9.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal-antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89.
Report of the task group on reference man. ICRP Publication 23 (1975). Ann ICRP. 4:III, 1980.
Fisher D, Rajon D, Breitz H, Goris M, Bolch W, Knox S. Dosimetry model for radioactivity localized to intestinal mucosa. Cancer Biother Radiopharm. 2004;19:293–307.
Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.
Boston RC, Greif PC, Berman M. Conversational SAAM – an interactive program for kinetic analysis of biological systems. Comput Programs Biomed. 1981;13:111–9.
Cobelli C, Foster DM. Compartmental models: theory and practice using the SAAM II software system. Adv Exp Med Biol. 1998;445:79–101.
Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, et al. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:985–94.
Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther. 2007;2:19–31.
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–34.
Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A. 2000;97:10701–5.
IMAP. Pharma & Biotech Industry Global Report – 2011. Istanbul: IMAP; 2011. p. 44.
Acknowledgments
We thank research assistants Christina Hong, Ernest Flatts, and Christine Pierre for their administrative support, Anabella Lindo, RN, and Susan Reyes, RN, for patient care, radiochemist Jing Qiao for radioiodination of the antibody, and the technologists of the Nuclear Medicine Service for their assistance in PET and PET/CT imaging of the patients.
Compliance with ethical standards
ᅟ
Conflicts of Interest
None.
Statement of human rights
All procedures performed in studies involving human participants were approved by the Institutional Review Board (IRB) of Memorial Sloan Kettering Cancer Center and were in accordance with the ethical standards of our institution and with the principles of the 1964 Declaration of Helsinki and its later amendments.
Statement on the welfare of animals
This article does not describe any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in this study.
Funding
This study was supported by the Ludwig Center for Cancer Immunotherapy and National Institutes of Health (NIH) grant numbers P50 CA 86438-11 and PO1 CA 33049.
Author information
Authors and Affiliations
Corresponding author
Additional information
Douglas Wong, and Lloyd J. Old were deceased.
Rights and permissions
About this article
Cite this article
Zanzonico, P., Carrasquillo, J.A., Pandit-Taskar, N. et al. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging 42, 1700–1706 (2015). https://doi.org/10.1007/s00259-015-3061-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-015-3061-2